Your browser doesn't support javascript.
loading
De-escalation of radiotherapy after primary chemotherapy in cT1-2N1 breast cancer (RAPCHEM; BOOG 2010-03): 5-year follow-up results of a Dutch, prospective, registry study.
de Wild, Sabine R; de Munck, Linda; Simons, Janine M; Verloop, Janneke; van Dalen, Thijs; Elkhuizen, Paula H M; Houben, Ruud M A; van Leeuwen, A Elise; Linn, Sabine C; Pijnappel, Ruud M; Poortmans, Philip M P; Strobbe, Luc J A; Wesseling, Jelle; Voogd, Adri C; Boersma, Liesbeth J.
Afiliación
  • de Wild SR; Department of Surgery, GROW School for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht, Netherlands. Electronic address: s.dewild@maastrichtuniversity.nl.
  • de Munck L; Department of Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, Netherlands.
  • Simons JM; Department of Surgery, GROW School for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht, Netherlands; Department of Radiotherapy, Erasmus Medical Centre, Rotterdam, Netherlands.
  • Verloop J; Department of Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, Netherlands.
  • van Dalen T; Department of Surgery, Erasmus Medical Centre, Rotterdam, Netherlands.
  • Elkhuizen PHM; Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, Netherlands.
  • Houben RMA; Department of Radiation Oncology, GROW School for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht, Netherlands.
  • van Leeuwen AE; Dutch Breast Cancer Research Group, Utrecht, Netherlands.
  • Linn SC; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, Netherlands.
  • Pijnappel RM; Department of Radiology, University Medical Centre Utrecht, Utrecht University, Netherlands.
  • Poortmans PMP; Department of Radiation Oncology, Iridium Netwerk, Antwerp, Belgium; Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
  • Strobbe LJA; Department of Surgery, Canisius Wilhelmina Hospital, Nijmegen, Netherlands.
  • Wesseling J; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, Netherlands.
  • Voogd AC; Department of Epidemiology, GROW School for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht, Netherlands; Department of Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, Netherlands; CAPHRI Care and Public Health Research Institute, Maastr
  • Boersma LJ; Department of Radiation Oncology, GROW School for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht, Netherlands.
Lancet Oncol ; 23(9): 1201-1210, 2022 09.
Article en En | MEDLINE | ID: mdl-35952707
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Oncología por Radiación Tipo de estudio: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Oncología por Radiación Tipo de estudio: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article